Table 1.
Demographic and clinical features of the patients
| Characteristics | Whole cohort (n = 48) | Patients with one unique sampling of anti-Jo-1 (n = 19) | Patients with at least 2 samplings of anti-Jo-1 (n = 29) | p-value |
|---|---|---|---|---|
| Age at diagnosisa | 53.9 ± 14.8 | 54.6 ± 15.8 | 53.5 ± 14.5 | 0.82 |
| Female/male | 35/13 | 12/7 | 23/6 | 0.22 |
| Duration of follow-up in monthsa | 93.6 ± 89.3 | 94.7 ± 106.8 | 93 ± 78.6 | 0.95 |
| Clinical featureb | ||||
| Myositis | 39 (81.3) | 15 (78.9) | 24 (82.8) | 0.74 |
| Arthralgia/arthritis | 39 (81.3) | 16 (84.2) | 23 (79.3) | 0.67 |
| Interstitial lung disease | 35 (72.9) | 12 (63.2) | 23 (79.3) | 0.22 |
| Mechanic’s hands | 22 (45.8) | 6 (31.6) | 16 (55.2) | 0.11 |
| Raynaud’s phenomenon | 10 (20.8) | 3 (15.8) | 7 (24.1) | 0.49 |
| Rash | 3 (6.3) | 1 (5.3) | 2 (6.9) | 0.82 |
| Digestive symptoms | 12 (25) | 1 (5.3) | 11 (37.9) | 0.011 |
| Treatment lines b | ||||
| Corticosteroids | 45 (93.8) | 18 (94.7) | 27 (93.1) | 0.82 |
| Methotrexate | 21 (43.8) | 8 (42.1) | 13 (44.8) | 0.85 |
| Azathioprine | 15 (31.3) | 5 (26.3) | 10 (34.5) | 0.55 |
| Rituximab | 11 (22.9) | 3 (15.8) | 8 (27.6) | 0.34 |
| Intravenous immunoglobulins | 9 (18.8) | 5 (26.3) | 4 (13.8) | 0.28 |
| Mycophenolate mofetil | 7 (14.6) | 1 (5.3) | 6 (20.7) | 0.14 |
| Cyclophosphamide | 4 (8.3) | 1 (5.3) | 3 (10.3) | 0.54 |
| Cyclosporin A | 1 (2.1) | 0 (0) | 1 (3.4) | 0.41 |
| Number of treatment linesa | 2.4 ± 1.2 | 2.2 ± 1 | 2.5 ± 1.3 | 0.29 |
aMean ± SD
bn (%)